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Abstract (150 words) 
Pregnancy and lactation has a unique effect on decisions relating to medication use. Medication 
safety can often be a great source of concern for women and healthcare professionals alike, 
leading to decisions that can negatively impact on outcomes. Compounding this is that 
evidence regarding the benefits and risks of medication use in pregnancy and lactation can 
often be lacking, contradictory or difficult to interpret and apply to clinical practice. 
Pharmacists represent a key source of information on medication use in pregnancy and lactation 
and as such play an essential role in optimising medication use. Notably, the role of pharmacists 
extends well beyond that of addressing concerns relating to medication safety, and includes 
contributing towards therapeutic decision making, providing ongoing medication management, 
and influencing patterns of medication use. Opportunities for improving health outcomes for 
mothers and their babies are aplenty and the time has come for pharmacists to stand up to the 
challenge and play their role. 
  






Women are commonly advised by various sources (including healthcare professionals, the 
media, or friends and family) against medication use during pregnancy and/or lactation unless 
the benefits of treating an illness outweigh the risks associated with treatment to both the 
mother and child. Unfortunately, information supporting medication use in pregnancy and/or 
lactation and evidence regarding benefits and risks is often lacking, contradictory or difficult 
to interpret and apply to clinical practice.1  
Medication use during pregnancy and lactation is extremely common, with the majority of 
women expected to take some form of non-prescription or prescription medication in the 
antenatal, perinatal (including labour/delivery) and/or postnatal period.2, 3 These medications 
are required for the optimal management of pre-existing chronic (i.e. diabetes) or acute (i.e. 
urinary tract infection) medical conditions, as well as the management of new conditions 
associated with pregnancy (i.e. gestational diabetes, nausea and vomiting) or lactation (i.e. 
mastitis). In a recent Australian study of women attending an antenatal clinic, 40% of women 
reported a chronic medical condition during pregnancy.2 This associated burden is likely to 
increase over time, with a greater number of women entering pregnancy with co-morbidities 
that require ongoing medical management, or that place them at greater risk of developing 
pregnancy complications requiring medical management.4 Existing challenges in decisions are 
further compounded through a need to consider and understand the impact of physiological 
changes that occur throughout pregnancy on the pharmacokinetics and pharmacodynamics of 
medication.5 In certain situations these may alter a medications therapeutic or toxic effects.5  
Pharmacists practicing in all healthcare settings often represent a key source of information 
on medication use in pregnancy and/or lactation. Despite this, information related to how 




pharmacists can specifically contribute towards optimising medication management during 
pregnancy and lactation remains scarce. Therefore, this pharmacy practice review aims to 
provide a summary on the role of pharmacists in optimising medication management during 
pregnancy and lactation, while paying specific focus on highlighting key challenges and 
importantly, opportunities for greater involvement. It also takes the unique approach of linking 
areas of greater pharmacist contributions with key components of practice, with the aim that 
this may provide the impetus for the future development of formal standards of practice in the 
area. 
Decisions Regarding Medication Use  
Pregnancy and lactation has a unique effect on decisions relating to medication use. 
Medication safety can often be a great source of concern for women and healthcare 
professionals alike, leading to decisions that can negatively impact on outcomes. Research 
has demonstrated that pregnant women frequently overestimate the risk of medication use 
and other exposures during pregnancy.6 In fact, it is not uncommon for pregnant women to 
become non-adherent to medications during pregnancy, often owing to misperception of risks 
associated with their use.7, 8 These decisions may also stem from a lack of perceived benefit 
of medication use, rather than safety alone. These concerns are not unique to women. An 
Australian survey demonstrated that, over 25% of doctors would instruct their pregnant 
patients to decrease or discontinue asthma medication during pregnancy where asthma was 
well controlled by that medication.9 This is despite knowledge of the potential harmful effects 
of worsening asthma on perinatal outcomes.9 
Notably, the opposite can also be true, with pregnant women, or indeed healthcare 
professionals, having a poor understanding of potential risks associated with using particular 
medications during pregnancy. For example, a survey identified that 26% of pregnant women 




were unaware of the adverse effects of using NSAIDs during late pregnancy.10 This 
highlights the importance of pharmacists in addressing misconceptions regarding medication 
use, both in relation to their harms and benefits.  
Categorising Medication Safety 
In response to the well documented thalidomide tragedy in the 1960s, in which more than 
10,000 children were born worldwide with major birth defects, the Australian Government 
established the Australian Drug Evaluation Committee (ADEC). This independent committee 
was responsible for advising on the safety of all medications introduced into Australia, and 
for monitoring and evaluating potential adverse effects of medications already in use. In 
recognition of the need to provide guidance regarding medication use in pregnancy, a specific 
working party was established by ADEC and this gave rise to a unique Australian 
categorisation of the risk of medications in pregnancy. Since then, ADEC has been replaced 
by the Advisory Committee on Prescription Medicines and its original ‘Medicines in 
pregnancy booklet’ has been replaced with the online ‘Prescribing medicines in pregnancy 
database’.11 Use of the pregnancy categories and related notes, however, has remained 
unchanged.  
Concerns regarding the current state of pregnancy risk classification and labelling have 
been well voiced.12 One of the greatest criticisms lies in its alphabetical nature, which may be 
misconstrued as a grading system, with levels of risk increasing from A to X. This can lead to 
misguided decisions regarding changes in medication therapy. For example, a decision may 
be made to change from sertraline (category C) to venlafaxine (category B3) in the belief that 
venlafaxine carries a safer pregnancy rating and would therefore be preferable to use. Further, 
use of categories can often lead to the erroneous belief that medications within the same 
category carry with them the same level of risk. For example, lamotrigine and sodium 




valproate are both listed as category D, however, evidence demonstrates that sodium 
valproate is associated with a much higher teratogenic potential than lamotrigine.13  
The overly simplistic nature and ready availability of the categories can lead to an 
overreliance on the category rating itself, without due reference to the quality and levels of 
evidence on which the categorisation was based. Further, categories are often assigned at the 
time when medications are marketed, often on the basis of animal data alone. As data 
emerges from human studies these categories are unlikely to change, meaning categories 
originally assigned may not reflect current state of evidence. There are pertinent recent 
examples of medications being given a more restrictive category based on new evidence. For 
example, in 2005 paroxetine was changed from category C to category D following the 
emergence of inconsistent data of an increased risk of congenital malformations, in particular, 
heart defects.14 However, it is extremely uncommon for a medication to be given a less 
restrictive category based on the emergence of new (and often reassuring) evidence. 
Rarely do the categorisations take into account important aspects like timing, dose, and 
route of exposure. For example, tetracycline are listed as category D, despite being safe to use 
during the first 18 weeks of pregnancy (16 weeks postconception) after which they may 
affect the formation of the baby's teeth and cause discolouration.11 The opposite can also 
occur, with the combination of amoxicillin and clavulanic acid listed as category B1, 
suggesting safety throughout pregnancy, but clinical recommendations advise against the use 
of this medication in women with premature rupture of the membranes as there may be an 
increased risk of neonatal necrotising enterocolitis.15 As such, blanket reference to categories 
alone is potentially misleading and could create unnecessary concern or harm.  
Reference to categories alone also fails to acknowledge the background risk of adverse 
pregnancy outcomes associated with all pregnancies, irrespective of medication exposure. 




This level of risk will differ according to other factors such as maternal smoking, advanced 
maternal age and co-morbidities (e.g. maternal overweight/obesity, pre-existing medical 
conditions). Understanding these factors is essential in identifying if medications increase the 
risk of adverse outcomes above the background risk, and what any absolute increase in risk 
actually is.  
Additional concerns relate to confusion generated from a misunderstanding of key 
differences between the Australian and US classification system, which are similar, but not 
interchangeable. Many are also of the erroneous belief that the pregnancy categories apply to 
lactation, which is not the case.12 Currently, there is no standardised endorsed approach 
towards the classification of medication use in lactation, although, different approaches are in 
use and will be commonly referenced by healthcare professionals. As with pregnancy 
categories, there should be a focus on individuals utilising their knowledge of underlying 
principles and available evidence to generate rational decisions, rather than use of categories 
alone.   
Regrettably, current categories alone are not the only source of misleading information, 
with information provided in Product Information (PI) also the subject of much criticism for 
being overly cautious in nature, often listing medication use in pregnancy and lactation under 
special precautions or contraindications.12 Such misleading information can often be further 
compounded by information obtained from the internet and lay sources.16 
Changes to Categorising Medication Safety 
Concerns around the use of pregnancy categories are not unique to the Australian 
landscape. Since 2008, the Federal Drug Administration (FDA) has taken significant steps 
towards major revisions to the labelling of prescription medications to allay such concerns. 
These changes incorporate the inclusion of a narrative labelling model, placing discussions 




regarding medication use in the context of the background risk of adverse outcomes, 
summarising how documented risks were identified (i.e. human vs. animal studies) and 
providing more information on clinical considerations such as medication dosing (where 
available).17 These changes are in the final stages of approval and will be gradually 
introduced over coming years, starting with newly listed medications. Only time will tell 
whether this change leads to improvements in the rational use of medications in pregnancy 
and lactation, and whether Australia introduces a similar labelling model. 
Despite their current limitations, given a heavy reliance on the use of safety categories by 
healthcare professionals and the public in clinical practice, any notion of just completely 
boycotting their use at this stage could appear misguided. In contrast, it highlights the need 
for pharmacists to develop a deeper understanding and appreciation of the role they play in 
clinical practice. If (or indeed when) changes are introduced, the removal of categories and 
the loss of what could be considered a safety blanket for many, may create additional 
demands, and opportunities, for pharmacists to contribute towards improved decision 
making. Pharmacists must use their expertise to look beyond these letters and numbers and 
make a more qualified assessment of the true benefits and risks. Evidence-based guides are 
available to assist in the critical appraisal and interpretation of research findings,18 and 
numerous references are available for providing detailed information (Table 1). In most 
cases, however, it is not always about having the answer, but rather knowing where to look. 
Potentially underused key resources are the specialist pregnancy and lactation medicines 
information services that exist across Australia, as well as overseas. Such Australian services 
differ greatly in respect to being limited to answering from healthcare professionals, while 
others also answer queries from the general public. Some services such as MotherSafe, also 
offer a number of fact sheets covering common queries in pregnancy and lactation that are 
able to be downloaded from their website. The receipt of sufficient funding to maintain the 




viability, reach and quality of these services is a consistent struggle within Australia, as well 
as internationally. In the current culture of centralisation, there is a concern that local 
specialist medicines information services could slowly be eroded, with the potential to 
negatively impact on service delivery and health outcomes. 
 
Pharmacist Education 
While pharmacists have recognised specialist knowledge on medications; including 
mechanisms of action, pharmacokinetics, clinical application of evidence, and assessment of 
adverse events, how well does this translate into areas of medication use in pregnancy and 
lactation? 
In the United States, concerns have been raised that current undergraduate pharmacy 
curricula are lacking in providing students with sufficient information on medication use in 
pregnancy and lactation.19, 20 While the delivery approach differs from standalone courses to 
the incorporation of content within other courses (i.e. pharmacology, pharmacokinetics), 59% 
of respondents from 81 schools/colleges of pharmacy felt that their current approach did not 
adequately cover this material.19 No data are available from an Australian perspective, but 
would be of interest.  
Such limitations with undergraduate education can have important implications for future 
clinical practice. For example, previous studies have demonstrated that pharmacists often do 
not feel adequately equipped to provide information on medication use in pregnancy and/or 
lactation.21  Further, when information is provided, it is not necessarily evidence-based and at 
times, inaccurate and based on their own opinions.21 While it is recognised that in a relatively 
evidence-free zone it can be difficult to separate personal experiences and anecdotes from 




fact, pharmacists should be able to integrate available information with their medication 
expertise, to make appropriate individual risk/benefit decisions.  
Notably, a recent survey undertaken to investigate the perspectives of community 
pharmacists in Australia on medication use and safety in breastfeeding identified that the 
majority of respondents (92%) were confident about supplying or counselling on medication 
during breastfeeding.22 Remarkably, however, over one-third were unaware that ibuprofen 
and metronidazole are compatible with breastfeeding, with a number of pharmacists 
providing advice to women to stop breastfeeding.22  This provides evidence that confidence is 
not always a good measure of competence.  
Optimising Therapeutic Outcomes 
Traditionally, investigating outcomes associated with medication use during pregnancy 
and lactation has tended to focus on safety, rather than efficacy. Pharmacists can play a 
greater role in optimising outcomes through various approaches, including; improved 
decision making on medication use at the point of prescribing, medication counselling 
(including adherence support) to address misconceptions, and therapeutic drug monitoring 
(TDM).  
Intervening at the point of prescribing/dispensing is likely to have the greatest impact, 
but is not always achievable. Similarly, contributing towards decisions prior to, rather than 
during, pregnancy is ideal. Provision of medication counselling can provide significant 
benefits in correcting misperceptions, allaying fears, and hopefully improve medication-
taking behaviour. An aspect not well investigated is the role of Home Medicines Reviews 
(HMRs) or Outpatient pharmacy services in contributing towards improvements in rational 
medication use.  




Despite awareness of alterations in pharmacokinetics during pregnancy, for many 
medications which have a wide therapeutic index, the clinical relevance of alterations in 
pharmacokinetics in pregnancy remains unclear. For medications which have a narrow 
therapeutic index, monitoring would be expected regardless of pregnancy status. 
Understanding how pregnancy impacts on pharmacokinetics is essential in making sounds 
judgements relating to TDM (i.e. aminoglycoside/antiepileptic drugs dosing).16 Further, there 
is still much work to be done and a significant role for pharmacists in determining the 
relevance of TDM programs and whether measuring drug concentrations during pregnancy 
ultimately improves outcomes beyond that already achieved through clinical judgement 
alone.16  
Outcome Evaluation 
While working in an area with much ambiguity can present many challenges for 
evidence-based practice, it offers many exciting possibilities for pharmacists to generate new 
evidence to guide best practice. Furthermore, many situations associated with medication use 
in pregnancy and/or lactation are unintentional or unavoidable. Integration of research within 
the clinical practice setting is essential in driving improvements in patient care and health 
outcomes and should be viewed as a core role for pharmacy practice.23  
Evidence may develop from drug utilisation studies, developing a greater understanding 
of current patterns of medication use and associated behaviours and progress to observational 
studies aimed at investigating clinical outcomes, such as the safety or efficacy of particular 
medications. Further, there may be opportunities for laboratory studies aimed at developing a 
greater understanding of medication pharmacokinetics in pregnancy, or the levels of 
medications in breast milk and the clinical evaluation of outcomes. In additional to all of this, 
there needs to be greater emphasis on the importance of presenting, publishing, interpreting 




and translating new evidence into practice as it is generated.24 Such endeavours are likely to 
benefit from greater training of pharmacists in research methods,23 and the improved 
collaboration, coordination and exchange of information between treatment/research settings.  
Future Directions 
Facilitating improvements in pharmacist’s contributions towards optimising medication 
management during pregnancy and lactation is likely to be multifactorial. There is a need for 
an assessment of the quality of undergraduate and postgraduate education as it pertains to 
medication use in pregnancy and lactation to ensure graduates and practicing pharmacists are 
adequately prepared to meet current and future demands. The formation of standards of 
practice and advanced pharmacy practice frameworks would assist in outlining key practice 
responsibilities, establishing core competency levels, and providing clear opportunities for 
career progression. An overview of such core pharmacist responsibilities and associated 
examples of practice are provided in Table 2. Hesitancies to contribute resources towards 
such a specialty area is likely to require the development of further evidence highlighting the 
positive impact of pharmacists in improving maternal and child outcomes. In addition, there 
is a need for further research into the advancement of pharmacy roles within non-standard 
areas of clinical practice in relation to medication use in pregnancy and lactation, such as the 
provision of home medicines reviews and outpatient services. Within professional 
organisations such as the Society of Hospital Pharmacists of Australia (SHPA) there exist 
opportunities for the formation of reference groups and support networks of pharmacists 
interested in enhancing current clinical care. In addition, integration with wider support and 
research networks beyond pharmacy are essential for individual continual development and 
opportunities for the development of new evidence to support future improvements in health 
outcomes. This includes opportunities for interdisciplinary engagement, which can be 
facilitated through membership of professional organisations such as the Society of Obstetric 




Medicine of Australia and New Zealand (SOMANZ) and the Perinatal Society of Australia 
and New Zealand (PSANZ). Lastly, there remains a key role for relevant professional 
organisations to lobby for additional support for pregnancy and lactation medicines 
information services. This should not just be restricted to organisations representing 
pharmacists, but also those representing key end users such as doctors and consumers. 
In conclusion, this practice review provides a unique perspective on the role that 
pharmacists can play in optimising medication management during pregnancy and lactation. 
It is anticipated that the summary of key references will become an invaluable resource in 
assisting pharmacists in obtaining the best available evidence, while it is also hoped that 
highlighting key components of practice through which pharmacists can contribute to 
improved health outcomes may provide impetus for the future development of formal 
standards of practice to drive improvements in clinical practice. Clinical pharmacy services 
will remain an integral part of the care of pregnant patients, especially as the obstetric 
population ages and has an increase in comorbid conditions, such as diabetes, heart disease 
and hypertension.4 The pharmacy profession needs to be ready and willing to accept this 
challenge and should be keen to adapt to enhanced roles. 
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Table 1. Summary of commonly used references for medication use in pregnancy and 
lactation 
Reference Countrya Free 
Access 
Comments 
Pregnancy and Lactation    
Australian Medicines Handbook 
https://www.amh.net.au/  
Australia No • Available in print and 
online 
• Updated at least yearly 
• Brief clinical 
recommendations for 
pregnancy and lactation 
available in medication 
monographs 
• Includes reference to 
pregnancy categoriesb 
Drugs in Pregnancy and Lactation: A 
Reference Guide to Fetal and 
Neonatal Risk 
 by Briggs, Freeman, Yaffe 
USA No • Available in print and 
online 
• Published approximately 
every 3 years 
• Includes thorough 
review of published 
clinical and experimental 
literature 






Australia No • Available in print and 
online 
• Provides clinical 
recommendations for the 
management of a number 
of disease types 
• Includes reference to 
pregnancy categoriesb 
• Classifies medications in 
lactation based on risk; 
compatible, caution, 
avoid (insufficient data), 
and avoidb 
Reprotox/TERIS USA No • Available online 
• Updated regularly 
• Includes thorough 
review of published 
clinical and experimental 
literature 





Canada Yes • Available online 




• Only contains links to 
previous studies 
undertaken by the 
Motherisk team 
• Does not include 




USA/Canada Yes • Available online 
• Fact sheets suitable for 
providing to patients 
• Does not include 
summaries for all 
medications 
Specialised Medicines Information 
Centres;  




Australia Yes • Available to answer 
queries from the general 
public as well as 
healthcare professionals 
Perinatal Psychotropic Medication 
Information Service 
Royal Women’s Hospital, Victoria 
www.ppmis.org.au 
Australia Yes • Available online 
• Fact sheets suitable for 
providing to patients 
• Only contains 
information on 






Pregnancy and Breastfeeding 
Medicine Guide 
Royal Women’s Hospital, Victoria 
Australia No • Available in print only 
• Published approximately 
every 3 years 
• Includes brief clinical 
recommendations for 
>900 medications 
• Includes reference to 
Australian pregnancy 
categoriesb 
Pregnancy Only    




Australia Yes • Available online 
• Includes very brief 
practice points for some 
medications 
• Mainly includes 
reference to Australian 
pregnancy categoriesb 




USA Yes • Available online 
• Updated regularly 




Medications and Mother’s Milk 
 by Thomas W. Hale 
USA No • Available in print and 
online 
• Published every 2 years 
• Classifies medications in 
lactation based on risk 
with L1 being the safest 
and L5 being 
contraindicatedb 
a Refers to country of publication. References may include information provided or 
reviewed by experts outside of that country.  
b Caution is advised regarding the use of medication safety categories as the sole basis of 
decision making as categories alone may not provide an accurate reflection of the benefit-








Table 2. Overview of key components of practice in which pharmacists contribute towards optimising medication management during 
pregnancy and lactationa 
Components of practice Examples of practice 
1. Contribution towards therapeutic decision making  
Pharmacists are responsible for:  
• Contributing towards therapeutic decision making by obtaining an accurate and 
complete medication history, and assessing current medication management. 
Recognising that medication use during 
pregnancy/lactation is common and that more women are 
entering pregnancy with pre-existing medical conditions 
• Utilising their specialist knowledge (pertaining to pharmacokinetic and 
therapeutic evidence of medication use during pregnancy and lactation) to 
improve selection, monitoring, and evaluation of individual medication 
treatments as part of the medication management plan.  
Describing the pathophysiology of pregnancy/lactation 
specific conditions and their associated management 
• Obtaining accurate evidence, regardless of the setting, regarding the associated 
benefits and risks of medication use in pregnancy and lactation and to ensure 
that such evidence is effectively communicated to women and their treating 
health professionals 
Knowledge and appropriate use of key evidence-based 
references and guidelines relating to medication use 
during pregnancy and lactation 
• Contributing towards an enhanced understanding of the condition and its 
associated treatment, with the objective of promoting self-management of the 
underlying condition (where applicable), and adherence to the medication 
treatment regimen.  
Providing education and advice regarding importance of 
medication adherence and management of underlying 
disease (e.g. asthma) during pregnancy  
2. Provision of ongoing medication management   
Pharmacists are responsible for:  
• Developing medication management plans and reviewing clinical progress, 
including investigating whether undesirable or unintended clinical effects may 
be related to medication treatment.  
Identifying side effects in the infant which may be 
associated with use of specific medications taken during 
late gestation or lactation 
• Initiating monitoring and intervention, including assessment of whether 
medication treatment is achieving therapeutic goals, and the recommendation 
for therapeutic drug monitoring where indicated.  
Recommending therapeutic drug monitoring of 
medications known to be subject to alterations in 
pharmacokinetics during pregnancy 
• Ensuring therapeutic drug monitoring, where indicated, is performed 
appropriately and for the provision of advice regarding interpretation of results 
and its implications for medication management. 
Interpreting laboratory tests and providing 
recommendations for treatment alterations and further 
monitoring  




• Identification of medication management issues impacting on the effectiveness 
or safety of medication treatment. 
Understanding the impact of severe nausea and vomiting 
of pregnancy on medication administration and 
absorption 
3. Influencing patterns of medicine use  
Pharmacists are responsible for:  
• Monitoring, assessing, and contributing to changes in existing and evolving 
trends related to medication use during pregnancy and lactation in order to 
improve quality use of medicines. 
Developing and implementing evidence-based 
guidelines; undertaking clinical audits 
a Components of practice modified from those outlined in the National Competency Standards Framework for Pharmacists in Australia25 
 
